癌变·畸变·突变 ›› 2019, Vol. 31 ›› Issue (5): 412-416.doi: 10.3969/j.issn.1004-616x.2019.05.014
余明辰, 吴楠, 孙冬琳, 金焰
收稿日期:2019-06-14
修回日期:2019-09-26
出版日期:2019-09-30
发布日期:2019-10-09
通讯作者:
金焰,E-mail:jinyan@ems.hrbmu.edu.cn
E-mail:jinyan@ems.hrbmu.edu.cn
作者简介:余明辰,E-mail:673899957@qq.com。
基金资助:
Received:2019-06-14
Revised:2019-09-26
Online:2019-09-30
Published:2019-10-09
摘要： 胶质母细胞瘤是最常见的、恶性程度最高的颅内肿瘤，其高度恶性生物学行为严重制约着肿瘤患者的总生存期。即便最积极的联合治疗，患者的中位生存期仅有15个月。因此，进一步完善胶质母细胞瘤的特异性标志物，对患者的诊断、预后和个体化治疗有重要的意义。本文将针对胶质母细胞瘤中存在的主要临床相关的遗传学和表观遗传学异常进行阐述。
中图分类号:
余明辰, 吴楠, 孙冬琳, 金焰. 胶质母细胞瘤分子标志物的研究进展[J]. 癌变·畸变·突变, 2019, 31(5): 412-416.
| [1] CANCER GENOME ATLAS RESEARCH N, BRAT D J, VERHAAK R G, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas[J]. N Engl J Med, 2015, 372(26):2481-2498. [2] GRAMATZKI D, KICKINGEREDER P, HENTSCHEL B, et al. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma[J]. Neurology, 2017, 88(15):1422-1430. [3] VERHAAK R G, HOADLEY K A, PURDOM E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1[J]. Cancer Cell, 2010, 17(1):98-110. [4] NOUSHMEHR H, WEISENBERGER D J, DIEFES K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma[J]. Cancer Cell, 2010, 17(5):510-522. [5] BHAT K P, SALAZAR K L, BALASUBRAMANIYAN V, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma[J]. Genes Dev, 2011, 25(24):2594-2609. [6] FRATTINI V, TRIFONOV V, CHAN J M, et al. The integrated landscape of driver genomic alterations in glioblastoma[J]. Nat Genet, 2013, 45(10):1141-1149. [7] DANUSSI C, AKAVIA U D, NIOLA F, et al. RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation[J]. Cancer Res, 2013, 73(16):5140-5150. [8] BRENNAN C W, VERHAAK R G, MCKENNA A, et al. The somatic genomic landscape of glioblastoma[J]. Cell, 2013, 155(2):462-477. [9] KRELL D, MULHOLLAND P, FRAMPTON A E, et al. IDH mutations in tumorigenesis and their potential role as novel therapeutic targets[J]. Future Oncol, 2013, 9(12):1923-1935. [10] XU W, YANG H, LIU Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases[J]. Cancer Cell, 2011, 19(1):17-30. [11] GROSS S, CAIRNS R A, MINDEN M D, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations[J]. J Exp Med, 2010, 207(2):339-344. [12] BLEEKER F E, ATAI N A, LAMBA S, et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma[J]. Acta Neuropathol, 2010, 119(4):487-494. [13] FU X, CHIN R M, VERGNES L, et al. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling[J]. Cell Metab, 2015, 22(3):508-515. [14] TURKALP Z, KARAMCHANDANI J, DAS S. IDH mutation in glioma:new insights and promises for the future[J]. JAMA Neurol, 2014, 71(10):1319-1325. [15] LI H, LI J, CHENG G, et al. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy[J]. Clin Neurol Neurosurg, 2016, 151:31-36. [16] HARTMANN C, HENTSCHEL B, TATAGIBA M, et al. Molecular markers in low-grade gliomas:predictive or prognostic?[J]. Clin Cancer Res, 2011, 17(13):4588-4599. [17] HOUILLIER C, WANG X, KALOSHI G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas[J]. Neurology, 2010, 75(17):1560-1566. [18] HURTT M R, MOOSSY J, DONOVAN-PELUSO M, et al. Amplification of epidermal growth factor receptor gene in gliomas:histopathology and prognosis[J]. J Neuropathol Exp Neurol, 1992, 51(1):84-90. [19] JAROS E, PERRY R H, ADAM L, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours[J]. Br J Cancer, 1992, 66(2):373-385. [20] SCHLEGEL J, MERDES A, STUMM G, et al. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma[J]. Int J Cancer, 1994, 56(1):72-77. [21] EKSTRAND A J, SUGAWA N, JAMES C D, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails[J]. Proc Natl Acad Sci U S A, 1992, 89(10):4309-4313. [22] HEIMBERGER A B, HLATKY R, SUKI D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvⅢ in glioblastoma multiforme patients[J]. Clin Cancer Res, 2005, 11(4):1462-1466. [23] SHINOJIMA N, TADA K, SHIRAISHI S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme[J]. Cancer Res, 2003, 63(20):6962-6970. [24] NARITA Y, NAGANE M, MISHIMA K, et al. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas[J]. Cancer Res, 2002, 62(22):6764-6769. [25] PHILLIPS H S, KHARBANDA S, CHEN R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis[J]. Cancer Cell, 2006, 9(3):157-173. [26] CLARKE I D, DIRKS P B. A human brain tumor-derived PDGFR-alpha deletion mutant is transforming[J]. Oncogene, 2003, 22(5):722-733. [27] OZAWA T, BRENNAN C W, WANG L, et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas[J]. Genes Dev, 2010, 24(19):2205-2218. [28] CANCER GENOME ATLAS RESEARCH N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways[J]. Nature, 2008, 455(7216):1061-1068. [29] ASSANAH M, LOCHHEAD R, OGDEN A, et al. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses[J]. J Neurosci, 2006, 26(25):6781-6790. [30] ASSANAH M C, BRUCE J N, SUZUKI S O, et al. PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain[J]. Glia, 2009, 57(16):1835-1847. [31] PHILPOTT C, TOVELL H, FRAYLING I M, et al. The NF1 somatic mutational landscape in sporadic human cancers[J]. Hum Genomics, 2017, 11(1):13. [32] BANERJEE S, BYRD J N, GIANINO S M, et al. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo[J]. Cancer Res, 2010, 70(4):1356-1366. [33] TOONEN J A, SOLGA A C, MA Y, et al. Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology[J]. J Exp Med, 2017, 214(1):17-25. [34] AMATYA V J, NAUMANN U, WELLER M, et al. TP53 promoter methylation in human gliomas[J]. Acta Neuropathol, 2005, 110(2):178-184. [35] BAEZA N, WELLER M, YONEKAWA Y, et al. PTEN methylation and expression in glioblastomas[J]. Acta Neuropathol, 2003, 106(5):479-485. [36] NAKAMURA M, YONEKAWA Y, KLEIHUES P, et al. Promoter hypermethylation of the RB1 gene in glioblastomas[J]. Lab Invest, 2001, 81(1):77-82. [37] COSTELLO J F, BERGER M S, HUANG H S, et al. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation[J]. Cancer Res, 1996, 56(10):2405-2410. [38] HEGI M E, DISERENS A C, GORLIA T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma[J]. N Engl J Med, 2005, 352(10):997-1003. [39] WICK W, PLATTEN M, MEISNER C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly:the NOA-08 randomised, phase 3 trial[J]. Lancet Oncol, 2012, 13(7):707-715. [40] ESTELLER M, GARCIA-FONCILLAS J, ANDION E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents[J]. N Engl J Med, 2000, 343(19):1350-1354. [41] HEGI M E, DISERENS A C, GODARD S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide[J]. Clin Cancer Res, 2004, 10(6):1871-1874. [42] HERRLINGER U, RIEGER J, KOCH D, et al. Phase Ⅱ trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma:UKT-03[J]. J Clin Oncol, 2006, 24(27):4412-4417. [43] DUCREST A L, SZUTORISZ H, LINGNER J, et al. Regulation of the human telomerase reverse transcriptase gene[J]. Oncogene, 2002, 21(4):541-552. [44] GERTLER R, ROSENBERG R, STRICKER D, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma[J]. J Clin Oncol, 2004, 22(10):1807-1814. [45] LU L, ZHANG C, ZHU G, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome[J]. Breast Cancer Res, 2011, 13(3):R56. [46] SANDERS R P, DRISSI R, BILLUPS C A, et al. Telomerase expression predicts unfavorable outcome in osteosarcoma[J]. J Clin Oncol, 2004, 22(18):3790-3797. [47] GRIEWANK K G, MURALI R, SCHILLING B, et al. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours[J]. Br J Cancer, 2013, 109(2):497-501. [48] HORN S, FIGL A, RACHAKONDA P S, et al. TERT promoter mutations in familial and sporadic melanoma[J]. Science, 2013, 339(6122):959-961. [49] KILLELA P J, REITMAN Z J, JIAO Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal[J]. Proc Natl Acad Sci U S A, 2013, 110(15):6021-6026. [50] IDERAABDULLAH F Y, VIGNEAU S, BARTOLOMEI M S. Genomic imprinting mechanisms in mammals[J]. Mutat Res, 2008, 647(1-2):77-85. [51] BAYLIN S B, ESTELLER M, ROUNTREE M R, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer[J]. Hum Mol Genet, 2001, 10(7):687-692. [52] TANWAR M K, GILBERT M R, HOLLAND E C. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma[J]. Cancer Res, 2002, 62(15):4364-4368. [53] KNOBBE C B, REIFENBERGER J, REIFENBERGER G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas[J]. Acta Neuropathol, 2004, 108(6):467-470. [54] SCHINDLER G, CAPPER D, MEYER J, et al. Analysis of BRAF V600E mutation in 1, 320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma[J]. Acta Neuropathol, 2011, 121(3):397-405. [55] KLEINSCHMIDT-DEMASTERS B K, AISNER D L, BIRKS D K, et al. Epithelioid GBMs show a high percentage of BRAF V600E mutation[J]. Am J Surg Pathol, 2013, 37(5):685-698. [56] KARAJANNIS M A, LEGAULT G, FISHER M J, et al. Phase Ⅱ study of sorafenib in children with recurrent or progressive low-grade astrocytomas[J]. Neuro Oncol, 2014, 16(10):1408-1416. [57] ROBINSON G W, ORR B A, GAJJAR A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy[J]. BMC Cancer, 2014, 14:258. [58] GUTTMAN M, RINN J L. Modular regulatory principles of large non-coding RNAs[J]. Nature, 2012, 482(7385):339-346. [59] SAHU A, SINGHAL U, CHINNAIYAN A M. Long noncoding RNAs in cancer:from function to translation[J]. Trends Cancer, 2015, 1(2):93-109. [60] KIM S S, HARFORD J B, MOGHE M, et al. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide[J]. Nucleic Acids Res, 2018, 46(3):1424-1440. [61] ZHANG L, WANG Q, WANG F, et al. LncRNA LINC01446 promotes glioblastoma progression by modulating miR-489-3p/TPT1 axis[J]. Biochem Biophys Res Commun, 2018, 503(3):1484-1490. [62] PASTORI C, KAPRANOV P, PENAS C, et al. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation[J]. Proc Natl Acad Sci U S A, 2015, 112(27):8326-8331. |
| [1] | 刘颖, 王可, 何杨婷, 肖金荣, 王唤卓, 李旸凯, 魏晟. 基于TCGA数据挖掘筛选肺鳞癌预后相关lncRNA分子标签[J]. 癌变·畸变·突变, 2018, 30(6): 468-472,478. |
| [2] | 高晓洁, 孔璐, 薛玉英. 纳米镍对大鼠睾丸生精-支持共培养细胞的凋亡作用及机制研究[J]. 癌变·畸变·突变, 2018, 30(1): 8-13,19. |
| [3] | 王全凯, 王博深, 谢广云, 康同影, 朱宝立, 许建宁. GMA诱导16HBE恶性转化细胞中LncRNA EMX2OS的表达及意义[J]. 癌变·畸变·突变, 2017, 29(6): 422-426. |
| [4] | 杨丽, 张小茜, 张孟贤. Notch信号通路对胶质瘤干细胞作用机制的研究进展[J]. 癌变·畸变·突变, 2017, 29(4): 322-324. |
| [5] | 刘平. 长链非编码RNA XIST和miR-101-3p在子宫颈癌组织中的表达及关系[J]. 癌变·畸变·突变, 2017, 29(2): 121-124. |
| [6] | 常晨, 赵霄瀚, 江烨, 徐昕, 蔡岩, 裴宇慧, 张钰, 郝佳洁, 王明荣. 食管鳞癌组织的常见基因组DNA异常改变及其临床预后的相关性分析[J]. 癌变·畸变·突变, 2017, 29(1): 1-6. |
| [7] | Bernd Kaina. 甲基化抗肿瘤药物治疗中的DNA修复:治疗效果与健康结局[J]. 癌变·畸变·突变, 2016, 28(5): 333-341,347. |
| [8] | 刘红梅, 王全凯, 谢广云, 温亚男, 许建宁. LncRNA PCA3在甲基丙烯酸环氧丙酯诱导16HBE恶性转化细胞中的表达及意义[J]. 癌变·畸变·突变, 2016, 28(3): 185-189. |
| [9] | 李夏君，杨 淼，董自成，刘 冉，尹立红，浦跃朴. LncRNA-UCA1与淮安食管癌发病风险的初步研究[J]. 癌变·畸变·突变, 2014, 26(6): 407-411. |
| [10] | 陈燕枝,卢山珊,万 丽,黄卡特,杨开颜. 不同分子分型的HR阴性乳腺癌临床病理特征及预后的研究[J]. 癌变·畸变·突变, 2013, 25(2): 139-143. |
| [11] | 梁 宇(综述),刘久华(审校). 尿路上皮癌中FGFR3基因的研究进展[J]. , 2011, 23(1): 72-074. |
| [12] | 李剑敏,万 丽,黄卡特. 原发性与继发性胶质母细胞瘤中MGMT与突变型P53蛋白表达的差异及其生物学意义[J]. , 2009, 21(2): 135-140. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
